Epidemiology of Lp(a) lipoprotein: Its role in atherosclerotic/thrombotic disease

Clinical Genetics

Volumn 52, Issue 5, 1997, Pages 281-292

  Djurovic, Srdjan ^a   Berg, Kåre ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Atherosclerosis; Coronary heart disease; Genetics; Immunochemical methods; Lp(a) lipoprotein; Methodology; Quantitative variation; Risk factor analysis

Indexed keywords

LIPOPROTEIN A;

ATHEROSCLEROSIS; CONFERENCE PAPER; CORONARY ARTERY DISEASE; CORONARY RISK; GENETIC EPIDEMIOLOGY; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; PRIORITY JOURNAL; THROMBOSIS;

EID: 0031426408     PISSN: 00099163     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0004.1997.tb04345.x     Document Type: Conference Paper

References (83)

1. Abe A, Noma A, Lee YJ, Yamaguchi H. Studies on apolipoprotein(a) phenotypes. Part 2. Phenotype frequencies and Lp(a) concentration in different phenotypes in patients with angiographically defined coronary artery diseases. Atherosclerosis 1992: 96: 9-15.
2. Alfthan G, Pekkanen J, Jauhiainen M, Pitkaniemi I, Karvonen M, Tuomilehto J, Salonen JT, Ehnhol C. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994: 106: 9-19.
3. Armstrong WV, Cremer P, Eberle E, Manke A, Schulze F, Wieland H, Kreuzer H, Seidel D. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Atherosclerosis 1986: 62: 249-257.
4. Assmann G, Schulte H, van Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996: 77: 1079-1084.
5. Badenhop RF, Wang XL, Wilcken DEL. Angiotensin-converting enzyme genotype in children and coronary events in their grandparents. Circulation 1995: 91: 1655-1658.
6. Bailleul S, Couderc R, Rossignol C, Fermanian J, Boutouchent F, Farnier MA, Etienne J. Lipoprotein(a) in childhood: relation with other atherosclerosis risk factors and family history of atherosclerosis. Clin Chem 1995: 41: 241-245.
7. Berg K. A new serum type system in man - the Lp system. Acta Pathol Microbiol Scand 1963: 59: 369-382.
8. Berg K. Confounding results of Lp(a) lipoprotein measurements with some test kits. Clin Genet 1994a: 46: 57-62.
9. Berg K. Genetics of coronary heart disease. In: Steinberg AG, Beam AG, Motulsky AG, Childs B, eds. Progress in medical genetics. Philadelphia: Saunders, 1983: 35-90.
10. Berg K. Inherited lipoprotein variation and atherosclerotic disease. In: Scanu AM, Wissler RW, Getz GS, eds. The Biochemistry of atherosclerosis. New York: Marcel Dekker Inc, 1979: 419-490.
11. Berg K. Lp(a) lipoprotein: a monogenic risk factor for cardiovascular disease. In: Goldbourt U, de Faire U, Berg K, eds. Genetic factors in coronary heart disease. Dordrecht/Boston/ London: Kluwer Academic Publishers, 1994b: 275-287.
12. Berg K. Lp(a) lipoprotein: an overview. Chemistry and Physics of Lipids 1994: 67/68: 9-16.
13. Berg K. Lp(a) lipoprotein: an overview. In: Scanu A, ed. Lipoprotein(a). New York: Academic Press, 1990: 1-23.
14. Berg K, Dahlén G, Børresen A-L. Lp(a) phenotypes, other lipoprotein parameters, and a family history of coronary heart disease in middle-aged males. Clin Genet 1979: 16: 347-352.
15. 1-lipoprotein in patients with coronary heart disease. Clin Genet 1974: 6: 230-235.
16. Berg K, Leren TP. Unchanged serum lipoprotein(a) concentrations with Lovastatin. Lancet 1989: ii: 812.
17. Bhatnagar D, Anand IS, Durrington PN, Patel DJ, Wander GS, Mackness MI, Creed F, Tomenson B, Chandrashekhar Y, Winterbottom M, Britt RP, Keil JE, Sutton GC. Coronary risk factors in people from the Indian subcontinent living in West London and their siblings in India. Lancet 1995: 345: 405-409.
18. Boerwinkle E, Menzel HJ, Kraft HG, Utermann G. Genetics of the quantitative Lp(a) lipoprotein trait. III. Contribution of Lp(a) glycoprotein phenotypes to normal lipid variation. Hum Genet 1989: 82: 73-78.
19. Bostom AG, Cypiles LA, Jenner JL, Ordovas JM, Seman LJ, Wilson PWF, Schaefer EJ, Castelli WP. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. JAMA 1996: 276: 544-548.
20. Bowden JF, Pritchard PH, Frohlich JJ. Lp(a) concentration and apo(a) isoform size. Relation to the presence of coronary artery disease in familial hypercholesterolemia. Arterioscler Thromb 1994: 14: 1561-1568.
21. Brown SA, Morrisett JD, Boerwinkle E, Hutchinson R, Patsch W. The relation of lipoprotein(a) concentrations and apolipoprotein(a) phenotypes with asymptomatic atherosclerosis in subjects of the Atherosclerosis Risk Communities (ARIC) Study. Arterioscler Thromb 1993: 13: 1558-1566.
22. Cremer P, Nagel D, Labrot B, Mann H, Muche R, Elster H, Seidel D. Lipoprotein(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest 1994: 24: 444-453.
23. Dahlén GH. Lipoprotein(a) in relation to atherosclerotic disease. Recent aspects on diagnosis and treatment of lipoprotein disorders. Impact on prevention of atherosclerotic disease. Prog Clin Biol Res 1988: 255: 27.
24. 1-lipoprotein in Swedish middle-aged males and in patients with coronary heart disease. Clin Genet 1975: 7: 334-341.
25. Dahlén GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM Jr. Association of levels of lipoprotein Lp(a), plasma lipids and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986: 74: 758-765.
26. Dahlén GH, Slunga L, Lindblom B. Importance of Lp(a) lipoprotein and HLA genotypes in atherosclerosis and diabetes. Clin Genet 1994: 46: 46-51.
27. Durovic S, März W, Frank S, Scharnagl H, Baumstark MW, Zechner R, Kostner GM. Decreased binding of apolipoprotein(a) to familial defective apolipoprotein B100 (Arg3500-Gln). A study of the assembly of recombinant apolipoprotein(a) with mutant low density lipoproteins. J Biol Chem 1994: 269: 30320-30325.
28. Durrington PN, Hunt L, Ishola M, Arrol S, Bhatnagar D. Apolipoproteins(a), AI, and B and parental history in men with early onset ischaemic heart disease. Lancet 1988: i: 1070-1073.
29. Farrer M, Game FL, Albers CJ, Neil HAW, Winocour PH, Laker MF, Adams PC, Alberti KGMM. Coronary artery disease is associated with increased lipoprotein(a) concentrations independent of the size of circulating apolipoprotein(a) isoforms. Arterioscler Thromb 1994: 14: 1272-1283.
30. Frick MH, Dahlén G, Berg K, Valle M, Hekali P. Serum lipids in angiographically assessed coronary atherosclerosis. Chest 1978: 73: 62-65.
31. Ghiselli G, Gaddi A, Barozzi G, Ciarrocchi A, Descovich G. Plasma lipoprotein(a) concentration in familial hypercholesterolemic patients without coronary artery disease. Metabolism: Clin Exp 1992: 41: 833-838.
32. Guo HC, Michel JB, Blouquit Y, Chapman MJ. Lipoprotein(a) and apolipoprotein(a) in a New World monkey, the common marmoset (Callitrix jacchus). Association of variable plasma lipoprotein(a) levels with a single apolipoprotein(a) isoform. Arterioscler Thromb 1991: 11: 1030-1041.
33. Haffner SM, Moss SE, Klein BE, Klein R. Lack of association between lipoprotein(a) concentrations and coronary heart disease mortality in diabetes: Wisconsin Epidemiologic Study of Diabetic Retinopathy. Metabolism 1992: 41: 194-197.
34. Halbmayer WM, Haushofer A, Radek J, Schön R, Deutsch M, Fischer M. Platelet size, fibrinogen and lipoprotein(a) in coronary heart disease. Coron Artery Dis 1995: 6: 397-402.
35. Hoefler G, Harnoncourt F, Paschke E, Mirtl W, Pfeiffer KH, Kostner GM. Lipoprotein(a): a risk factor for myocardial infarction. Arteriosclerosis 1988: 8: 398-401.
36. Howard BV, Le NA, Belcher JD, Flack JM, Jacobs DR, Lewis CE, Marcovina SM, Perkins LL. Concentrations of Lp(a) in Black and White young adults: relations to risk factors for cardiovascular disease. Ann Epidemiol 1994: 4: 341-350.
37. Hunninghake DB, Stein EA, Mellies MJ. Effects of one year treatment with pravastin, an HMG CoA reductase inhibitor, on lipoprotein(a). J Clin Pharmacol 1993: 33: 574-580.
38. Islam S, Gutin B, Smith C, Treiber F, Kamboh MI. Association of apolipoprotein(a) phenotypes in children with family history of premature coronary artery disease. Arterioscler Thromb 1994: 14: 1609-1616.
39. Jauhiainen M, Koskinen P, Ehnholm C, Frick MH, Manttari M, Manninen V, Huttunen JK. Lipoprotein(a) and coronary disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 1991: 89: 59-67.
40. Kark JD, Sandholzer C, Friedlander Y, Utermann G. Plasma Lp(a), apolipoprotein(a) isoforms and acute myocardial infarction in men and women: a case-control study in the Jerusalem population. Atherosclerosis 1993: 98: 139-151.
41. Karmansky I, Shnaider H, Palant A, Gruener H. Lysine-binding species of lipoprotein(a) in coronary artery disease. Eur J Clin Invest 1994: 24: 360-366.
42. Klausen IC, Beisiegel U, Menzel HJ, Rosseneu M, Nicaud V, Faergeman O (on behalf of the EARS Group). Apo(a) phenotypes and Lp(a) concentrations in offspring of men with and without myocardial infarction (The EARS Study). Arterioscler Thromb Vasc Biol 1995: 15: 1001-1008.
43. Klein G, Brugger P, Kullich W, Marth E, Kostner GM. Lipoprotein-Lp(a) als Risikofaktor für den Herzinfarkt: Eine Familienstudie. Wien Med Wochenschr 1984: 18: 403-408.
44. Kostner G, Avogaro P, Cazzolato G, Marth E, Bittolo-Bon G, Quinci GB. Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis 1981: 33: 51-61.
45. Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow JL. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation 1989: 80: 1313-1319.
46. Kraft HG, Lingelhel A, Köchl S, Hoppichler F, Kronenberg F, Abe A, Mühlberger V, Schönitzer D, Utermann G. Apolipoprotein (a) kringle IV repeat number predicts risk for coronary heart disease. Arterioscler Thromb Vasc Biol 1996: 16: 713-719.
47. Krempler F, Kostner GM, Bolzano K, Sandhofer F. Turnover of lipoprotein(a) in man. J Clin Invest 1980: 65: 1483-1490.
48. Labeur C, Rosseneu M, Henderson O. International Lp(a) standardisation. Chem Phys Lipids 1994: 67/68: 265-270.
49. Leren TP, Hjermann I, Berg K, Leren P, Foss OP, Viksmoen L. Effects of Lovastatin alone and in combination with cholestyr-amine on serum lipids and apolipoproteins in heterozygotes for familial hypercholesterolemia. Atherosclerosis 1988: 73: 135-141.
50. Maartmann-Moe K, Berg K. Lp(a) lipoprotein enters cultured fibroblasts independently of the plasma membrane low density lipoprotein receptor. Clin Genet 1981: 20: 352-362.
51. Mancini PF, Mooser V, Guerra R, Hobbs HH. Sequence microheterogeneity in apolipoprotein(a) gene repeats and the relationship to plasma Lp(a) levels. Hum Mol Genet 1995: 4: 1535-1542.
52. Marcovina SM, Albers JJ, Jacobs DR Jr, Perkins LL, Lewis CE, Howard BV, Savage P. Lipoprotein(a) concentrations and apolipoprotein(a) phenotypes in Caucasians and African Americans. Arterioscler Thromb 1993: 13: 1037-1045.
53. Marquez A, Mendoza S, Carrasco H, Hamer T, Glueck CJ. High lipoprotein(a) in children from kindreds with parental premature myocardial infarction. Pediatr Res 1993: 34: 670-674.
54. März W, Grutzmacher P, Paul D, Siekmeier DR, Schoeppe W, Gross W. Effect of lovastatin (20-80 mg daily) on lipoprotein fractions in patients with severe primary hypercholesterolemia. Int J Clin Pharmacol Ther 1994: 32: 92-97.
55. März W, Siekmeier R, Gross W, Kostner GM. Determination of lipoprotein(a): evaluation of three methods. Eur J Clin Chem Clin Biochem 1993: 31: 295-301.
56. Mbewu AD, Bhatnagar D, Durrington PN, Hunt L, Ishola M, Arrol S. Serum lipoprotein(a) in patients heterozygous for familial hypercholesterolemia, their relatives, and unrelated control populations. Arterioscler Thromb 1991: 11: 940-946.
57. Murai A, Miyahara T, Fujimoto N, Matsuda M, Kameyama M. Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis 1986: 59: 199-204.
58. Parlavecchia M, Pancaldi A, Taramelli R, Valsania P, Galli P, Pozza G, Chierchia S, Ruotoli G. Evidence that apolipoprotein(a) phenotype is a risk factor for coronary artery disease in men <55 years of age. Am J Cardiol 1994: 74: 346-351.
59. Rhoads GG, Dahlén G, Berg K, Morton NE, Dannenberg AL. Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA 1986: 256: 2540-2544.
60. Ridker PM, Hennekens CH. Commentary: lipoprotein(a) and risk of cardiovascular disease. Ann Epidemiol 1994: 4: 360-362.
61. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 1993: 270: 2195-2199.
62. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein(a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. BMJ 1990: 301: 1248-1251.
63. Sandholzer C, Saha N, Kark JD, Rees A, Jaross W, Dieplinger H, Hoppichler F, Boerwinkle E, Utermann G. Apo(a) isoforms predict risk for coronary heart disease. A study in six populations. Arterioscler Thromb 1992: 12: 1214-1226.
64. Sandkamp M, Funke H, Schulte H, Kohler E, Assmann G. Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age. Clin Chem 1990: 36: 20-23.
65. Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis Ce, Abolafia JM, Lippel K, Levy RI. Lipoprotein(a) levels and risk of coronary heart disease in men. JAMA 1994: 271: 999-1003.
66. Schreiner PJ. Lipoprotein(a) as a risk factor for preclinical atherosclerosis disease in a biracial cohort: the Atherosclerosis Risk in Communities (ARIC) Study. Chem Phys Lipids 1994: 67/68: 405-410.
67. Schwartzkopff W, Schleicher J, Pottins L, Yu S-B, Han C-Z, Du D-Y. Lipids, lipoproteins, apolipoproteins and other risk factors in Chinese men and women with and without myocardial infarction. Atherosclerosis 1990: 82: 253-259.
68. Seed M, Hoppichler F, Reaveley D, McCarthy S, Thompson GR, Boerwinkle E, Utermann G. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med 1990: 322: 1494-1499.
69. Sigurdsson G, Baldursdottir A, Sigvaldason H, Agnarsson U, Thorgeirsson G, Sigfusson N. Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol 1992: 69: 1251-1254.
70. Simons L, Friedlander Y, Simons J, McCallum J. Lipoprotein(a) is not associated with coronary artery heart disease in the elderly: cross-sectional data from the Dubbo study. Atherosclerosis 1993: 99: 87-95.
71. Soutar AK, McCarthy SN, Seed M, Knight BL. Relationship between apolipoprotein(a) phenotype, lipoprotein(a) concentration in plasma, and low density lipoprotein receptor function in a large kindred with familial hypercholesterolemia due to the pro664 - leu mutation in the LDL gene. J Clin Invest 1991: 88: 483-492.
72. Srinivasan SR, Dahlén GH, Jarpa RA, Webber LS, Berenson GS. Racial (Black-White) differences in serum lipoprotein(a) distribution and its relation to parental myocardial infarction in children. Bogalusa Heart Study. Circulation 1991: 84: 160-167.
73. Terres W, Tasis E, Pfalzer B, Beil FU, Beisiegel U, Hamm CW. Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein(a). Circulation 1995: 91: 948-950.
74. Utermann G, Kraft HG, Menzel H, Hopferwieser T, Seitz C. Genetics of the quantitative Lp(a) lipoprotein trait. I. Relation of Lp(a) glycoprotein phenotypes to Lp(a) lipoprotein concentrations in plasma. Hum Genet 1988a: 7: 41-46.
75. Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmier HG, Seitz C. Lp(a) glycoprotein phenotypes. J Clin Invest 1987: 80: 458-465.
76. Utermann G, Duba C, Menzel H. Genetics of the quantitative Lp(a) lipoprotein trait. II. Inheritance of Lp(a) glycoprotein phenotypes. Hum Genet 1988b: 78: 47-50.
77. Vessby B, Kostner G, Lithell H, Thomis J. Diverging effects of cholestyramine on apolipoprotein B and lipoprotein Lp(a). A dose-response study of the effects of cholestyramine in hypercholesterolemia. Atherosclerosis 1982: 44: 61-71.
78. Wald NJ, Law M, Watt HC, Wu T, Bailey A, Johnson AM, Craig WY, Ledue TB, Haddow JE. Apolipoproteins and ischaemic heart disease: implications for screening. Lancet 1994: 343: 75-79.
79. Watts GF, Kearney EM, Taub NA, Slavin BM. Lipoprotein(a) as an independent risk factor for myocardial infarction in patients with common hypercholesterolemia. J Clin Pathol 1993: 46: 267-270.
80. Wiklund O, Angelin B, Olofsson SO, Eriksson M, Fager G, Berglund L. Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia. Lancet 1990: 335: 1360-1363.
81. Wilcken DEL, Wang XL, Dudman NPB. The relationship between infant and parent Lp(a) levels. Chem Phys Lipids 1994: 67/68: 299-304.
82. Wild SH, Fortmann SP, Marcovina SM. A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Standford Five-City Project participants. Arterioscler Thromb Vasc Biol 1997: 17: 239-245.
83. Wottawa A, Fromme K, Klein G. Lipoprotein(a) bei koronarer Herzkrankheit und Myokardinfarkt. Münch Med Wochenschr 1984: 126: 53-55.